Ozekinci T, Ozbek E, Celik Y
Department of Microbiology, Faculty of Medicine, University of Dicle, Diyarbakir, Turkey.
J Int Med Res. 2007 Sep-Oct;35(5):696-703. doi: 10.1177/147323000703500515.
There is substantial evidence that the detection of T cells specific for the proteins ESAT-6 and CFP-10 using the ex vivo enzyme-linked immunospot technique is a marked improvement on the existing tuberculin skin test (TST). This new technique, which detects gamma-interferon-producing T cells, is now available as the commercial assay, T-Spot.TB. We compared the T-Spot.TB test with the TST for the diagnosis of latent tuberculosis infection (LTBI) in different groups of subjects. Significant accordance (85.7%) between the tests was found in subjects with active lung tuberculosis and in tuberculosis clinic and laboratory personnel (63.6%) but accordance was lowest and not significant amongst house contacts of tuberculosis patients (53.6%). We conclude that, in countries where vaccination is routinely performed, the T-Spot.TB test is a useful diagnostic test for LTBI in high-risk groups when carried out either together with the TST and/or to confirm the TST result.
有大量证据表明,采用体外酶联免疫斑点技术检测针对ESAT-6和CFP-10蛋白的特异性T细胞,相对于现有的结核菌素皮肤试验(TST)有显著改进。这项检测产生γ-干扰素的T细胞的新技术现已作为商业化检测方法T-Spot.TB可用。我们比较了T-Spot.TB检测与TST在不同受试者组中诊断潜伏性结核感染(LTBI)的情况。在活动性肺结核患者以及结核病诊所和实验室工作人员中,两种检测方法有显著一致性(85.7%),但在结核病患者的家庭接触者中一致性最低且不显著(53.6%)。我们得出结论,在常规进行疫苗接种的国家,当与TST一起进行和/或用于确认TST结果时,T-Spot.TB检测对于高危人群的LTBI是一种有用的诊断检测方法。